Toroso Investments LLC Raises Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Toroso Investments LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 12.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 70,221 shares of the biopharmaceutical company’s stock after purchasing an additional 7,679 shares during the period. Toroso Investments LLC’s holdings in Gilead Sciences were worth $4,175,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Arrowstreet Capital Limited Partnership raised its position in Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after buying an additional 13,764,169 shares during the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences during the 4th quarter worth about $950,911,000. Capital World Investors boosted its stake in shares of Gilead Sciences by 16.0% during the 1st quarter. Capital World Investors now owns 49,501,852 shares of the biopharmaceutical company’s stock worth $2,942,905,000 after purchasing an additional 6,820,228 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Gilead Sciences by 70.6% during the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after acquiring an additional 6,410,047 shares during the period. Finally, First Trust Advisors LP lifted its holdings in shares of Gilead Sciences by 103.4% during the 1st quarter. First Trust Advisors LP now owns 6,126,685 shares of the biopharmaceutical company’s stock worth $364,232,000 after acquiring an additional 3,114,535 shares during the period. Institutional investors and hedge funds own 78.58% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on GILD. BMO Capital Markets began coverage on shares of Gilead Sciences in a research report on Tuesday, June 7th. They issued a “hold” rating and a $63.00 price objective for the company. StockNews.com downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 17th. Piper Sandler raised their price target on shares of Gilead Sciences from $74.00 to $79.00 in a research report on Monday. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $63.00 to $74.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Finally, TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Monday, August 15th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and an average price target of $73.47.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $65.18 on Thursday. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.30. The firm’s 50-day simple moving average is $62.90 and its 200 day simple moving average is $61.84. Gilead Sciences, Inc. has a fifty-two week low of $57.17 and a fifty-two week high of $74.12. The stock has a market cap of $81.69 billion, a P/E ratio of 19.87, a P/E/G ratio of 0.67 and a beta of 0.31.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Thursday, September 15th will be given a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 4.48%. The ex-dividend date is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 89.02%.

Gilead Sciences Company Profile

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Stories

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.